Opioid firm Insys files for Chapter 11

Opioid manufacturer Insys Therapeutics filed for bankruptcy protection Monday, days after agreeing to pay $225 million to settle a federal investigation into the marketing practices for its powerful fentanyl painkiller.

The company said it would continue operating while it comes up with a plan to pay its creditors, including the Justice Department, under Chapter 11 of the federal bankruptcy code. Under an agreement released last week with the U.S. government, the company has promised to divest of Subsys, its lead product and the painkiller that had come under scrutiny.

The company was accused of bribing doctors to prescribe its product and misleading insurers about patients’ need for the drug. Subsys, an under-thetongue spray, was approved only for cancer patients who were already taking round-the-clock opioid painkillers.

As part of the deal last week, Insys agreed to plead guilty to five counts of mail fraud and pay a $2 million fine and $28 million in forfeiture. The company also said it would pay $195 million to settle allegations that it violated the federal False Claims Act, which involves defrauding the U.S. government through drug sales to health care programs like Medicare.

In court filings Monday, the company said it had entered into an agreement with the federal government that would cap the recovery amount at $195 million.

In May, a federal jury in Boston found the company’s top executives, guilty of conspiring to fuel sales of Subsys, by bribing doctors and misleading insurance companies.